NovoMix® 30 FlexPen® Insulin weputara uzo abuo

Ngwakọta ọrụ: 1 ml nke nkwusioru nke ogwu ogbugba nwere 100 IU / ml nke insulin aspart (rDNA) (30% insulin aspart na 70% insulin aspart crystallized with protamine)

Mkpịsị sirinji 1 nwere milimita 3, nke ya na nkeji 300 rọrọ

Otu (OD) bụ 6 nmol ma ọ bụ 0.035 mg nke insulin na-agagharị agagharị nke ukwuu,

Ndị na-ahụ maka ihe: glycerin, phenol, metacresol, zinc chloride, sodium chloride, sodium phosphate, mmiri mmiri, protamine sulfate, sodium hydroxide, acid hydroelo, dilution hydrochloric acid, mmiri maka injection.

Ngwongwo ogwu

NovoMix ® 30 FlexPen ® bụ nkwụsị nke nwere usoro abụọ nke insulin aspart (analog na-arụ ọrụ obere oge) yana insulin crystallized insulin na anaali insulin na-eme ka obere. Mwepu ahụ nwere insulin nke obere ihe dị mkpụmkpụ na oge ogologo oge nke ime ihe na 30/70. Site na ntinye nke otu molar ubara, insulin aspart bu ihe nkpa nye insulin mmadu.

Mmetụta dị ala nke insulin na-eme bụ ịkwalite mbido nke glucose site na anụ ahụ mgbe ọ jikọsịrị insulin na ndị na-anabata uru ahụ na mkpụrụ ndụ, yana mgbochi nke mwepụta nke glucose site na imeju.

NovoMix ® 30 FlexPen ® na-amalite ime 10-20 nkeji mgbe nchịkwa ọgwụ ahụ gasịrị. Mmetụta kasịnụ na-etolite awa iri na anọ mgbe nchịkwa gachara. Oge ime ihe ruru awa 24.

Na omumu ihe omumu nke diri onwa ato ma jiri nlebara anya NovoMix ®30 FlexPen ® na insulin nke mmadu 30 tupu nri ututu na nri abali n’ime ndi oria nke oria oria nke II, egosiputara ya na ntinye NovoMix ® 30 FlexPen ® glucose obara. Mgbe nri ha abụọ (nri ụtụtụ na nri abalị), belata nke ukwuu ma e jiri ya rụọ ọrụ insulin nke mmadụ bi 30.

Mgbe ị na-eme usoro nyocha-meta, nke gụnyere ọnwụnwa nyocha 9 nke ndị ọrịa nwere ụdị nke m na ụdị shuga II, a chọpụtara na, ma e jiri ya tụnyere insulin nke mmadụ bi na 30, ojiji nke NovoMix ®30 tupu nri ụtụtụ na nri abalị na-eduga n'ịchịkwa glucose ọbara ọbara postprandial dị oke mma (dịka mmụba nke glucose ọbara mgbe nri ụtụtụ, nri ehihie na nri abalị).

N'agbanyeghị eziokwu ahụ bụ na glucose ọnụ na-ebu ọnụ dị elu na ndị ọrịa na-anata ọgwụgwọ NovoMix ®30, ọkwa nke glycosylated haemoglobin, bụ ihe na-egosi njikwa glycemic zuru oke, bụ otu.

N'ime nyocha ụlọ ọgwụ, ndị ọrịa nwere ọrịa shuga II (341 ndị mmadụ), ndị kewara n'ime otu dị ka ụkpụrụ siri ike, natara naanị NovoMix or 30 ma ọ bụ NovoMix ® 30 na ngwakọta na metformin ma ọ bụ metformin tinyere sulfonylureas. Mgbe izu 16 gachara, ịta ahụhụ nke HbA 1c n'ime ndị ọrịa na-anata NovoMix ® 30 yana metformin ma ọ bụ metformin na sulfonylurea bụ otu. N'ime ọmụmụ a, na 57% nke ndị ọrịa, ntinye uche nke HbA 1c dị elu karịa 9%. N'ime ndị ọrịa a, mgbe ha na-agwọ NovoMix ® 30 na metformin, mbelata nke HbA 1c dị mkpa karịa na njikọta nke metformin na sulfonylurea.

N'ime nyocha nke ndị ọrịa shuga nke II, nke njikwa glycemic na-eji naanị ọgwụ hypoglycemic ọgwụ adịghị arụ ọrụ, a na-eji nlekọta NovoMix 30 (117 ndị ọrịa) ugboro abụọ kwa ụbọchị na nchịkwa insulin glargine (116 ndị ọrịa). Ka izu 28 gachara, NovoMix â 30 tinyere nhọrọ ị doseụ ọgwụ, ọkwa HbA 1C belatara site na 2.8% (nkezi uru nke HbA 1C mgbe esonyere n'ọmụmụ = 9.7%). N'oge ọgwụgwọ NovoMix â 30, 66% nke ndị ọrịa ruru ọkwa HbA 1C n'okpuru 7%, na 42% ruru ndị ọrịa n'okpuru 6.5%, ebe ịbara plasma glucose ịbelata belata ihe dị ka 7 mmol / L (site na 14.0 mmol / l tupu ọgwụgwọ ruo 7.1 mmol / l).

Mgbe ị na-eme usoro nyocha nke meta na ndị ọrịa nwere ọrịa shuga nke II, a chọpụtara na na NovoMix® 30 n'ihe ize ndụ nke ịmalite hypoglycemia n'abalị na hypoglycemia dị ala ma e jiri ya tụnyere insulin mmadụ na-arịa ọrịa 30. N’otu oge ahụ, ihe ize ndụ nke ọrịa hypoglycemia n’ụbọchị bụ dị elu na ndị ọrịa na-anata NovoMix ® 30.

Childrenmụaka na ndị nọ n'afọ iri na ụma. Ọmụmụ ihe izu iri na isii emere na ndị ọrịa 167 dị afọ 10-18 ka atụnyere ịdị adị nke ijigide nchịkwa postprandial site na nchịkwa NovoMix 30 na nri na-eji insulin / biphasic mmadụ mmadụ 30 na nri insulin NPH tupu ụra. N'ime oge ọmụmụ ahụ na otu abụọ ahụ, itinye uche nke HbA 1C nọgidere na ọkwa ahụ agụnyere n'ọmụmụ ihe ahụ, na enweghị ọdịiche dị n'etiti ọnya hypoglycemia n'etiti NovoMix 30 na insulin nke mmadụ 30.

Na omumu ihe omumu nke gbara okpukpu abuo (ihe dika izu iri na abuo maka ihe o bula) emere na obere umuaka (ndi mmadu 54) N’agbata afọ isii na isii rue afọ isii, mmụba nke ọnụọgụ hypoglycemia na glucose dị ọnụ ọgụgụ gbadata agbadata mgbe ejiri NovoMix â 30 E jiri ya tụnyere insulin nke mmadụ biburu nke 30. ogo HbA 1C na ngwụcha ọgwụgwọ gwọchara otu ahụ na-anata insulin nke mmadụ 30 dịka nke NovoMix 30.

Ndị agadi. Amụrụ ọgwụ ọgwụ nke NovoMix â 30 n'ime ndị ọrịa agadi. Ka osila di, emere ihe omumu ihe omimi nke gbara okpukpu abuo na ntughari anya nke ndi mmadu na acho insulin aspart na insulin nke mmadu nwere na udiri oria iri na itolu nke oria 65-83 gbara afo 65-83 (putara afọ iri asaa). Otu ọdịiche dị na ọgwụ ọgwụ (GIR max, AUC GIR, 0-120 min) mgbe nchịkwa aspart insulin ma ọ bụ insulin nke mmadụ na ndị ọrịa a bụ otu ndị ahụike ma ọ bụ ndị ọrịa nwere ọrịa shuga.

Na insulin aspart, amino acid proline na ọnọdụ nke 28 nke B n’ụyọkọ insulin nke mmiri ọgwụ ana-agbanwe dobere site na aspartic acid, na-ebelata nguzobe nke hexamers, dịka e kwuru na nkwadebe insulin nke mmadụ nwere. N'ime oge sovoble NovoMix 30, nke insulin aspart bụ 30% nke insulin niile, ọ na-abanye n'ime ọbara site na anụ ahụ dị n'okpuru ngwa ngwa karịa insulin nke insulin nke mmadụ na-arịa. 70% fọdụrụ dị n'ụdị crystalline nke protamine-insulin aspart, nnabata ahụ nke ogologo ya na nke ahụ bụ nke insulin NPH mmadụ. Oke nlebara anya nke insulin na ọbara ọbara mgbe iwebata NovoMix 30 dị 50% karịa, ma oge iji ruo ya bụ ọkara nke insulin nke mmadụ biphas 30. N'ime ndị ọrụ afọ ofufo ahụike, mgbe nchịkwa okirikiri NovoMix 30 dị na 0.20 U / n'arọ nke oke ahụ, oke ịta. emechara insulin aspart mechaa mgbe nkeji 60, ọ bụ 140 ± 32 pmol / L. Ọkara ọkara nke NovoMix ® 30 (t½), nke gosipụtara ọnụego nnabata nke urua protamine dị ihe dịka awa 8-9. Ọbara insulin insulin laghachiri na ntọala 15-18 awa mgbe nchịkwa subcutaneous gasịrị. N'ime ndị ọrịa nwere ụdị ọrịa shuga 2, a na-agbakarị ịta ahụ kachasị nkeji 95 mgbe nchịkwa gachara ma nọgidesie ike na ntọala ahụ opekata mpe 14.

Ndị agadi. Amụrụ ọgwụ ọgwụ nke NovoMix â 30 na ndị ọrịa agadi. Agbanyeghị, ọdịiche dị n'etiti ụkpụrụ nke ọgwụ pharmacokinetics mgbe nchịkwa insulin aspart ma ọ bụ insulin nke mmadụ na ndị ọrịa nwere ụdị ọrịa shuga nke II (65-83 afọ, nkezi afọ 70) bụ otu ihe ahụ na ndị mmadụ ma ọ bụ ndị ọrịa nwere ọrịa shuga na-eto eto. N'ime ndị ọrịa agadi na ndị okenye, mmịpụta ahụ na-agbadata, dịka egosiri na ọ ogologo oge iji rute insulin n'ọbara kachasị elu ọbara (82 min nwere etiti etiti 60-120 min). Uru nke C max bụ otu na ndị ọrịa nwere ọrịa shuga nke 2 dị obere yana ntakịrị ntakịrị karịa na ndị ọrịa nwere ụdị shuga 1.

Ndị nwere akụrụngwa arụ na arụ ọrụ hepatic.

Agụghị ọgwụ ọgwụ nke NovoMix ® 30 na ndị ọrịa nwere nsogbu gbasara akụrụngwa ma ọ bụ ọrụ ịwa ọria.

Childrenmụaka na ndị nọ n'afọ iri na ụma. Beenmụta ọgwụ ọgwụ nke NovoMix â 30 na amụghị ụmụaka na ndị ntorobịa. Agbanyeghị, na ụmụaka (6-12 afọ) na ụmụaka (13-17 afọ) na-arịa ọrịa shuga 1, a mụrụ ọgwụ ọgwụ na ọgwụ ọgwụ nke soluble aspart insulin. Ọ nabatara ngwa ngwa na ndị ọrịa nke otu abụọ ahụ, ebe ụkpụrụ t kachasị dị ka ndị okenye. Ka ọ dị ugbu a, ọnụahịa nke C max na afọ dị iche iche dịgasị iche iche, nke na-egosi ịdị mkpa nke nhọrọ insulin na-anwale otu.

Data Nchekwa nke ime.

Ihe omimi preclinical nwetara na ndabere nke ihe omumu gbasara ọdịnala na nchekwa ọgwụ, egbu egbu nke ọgwụ a na -eme ugboro ugboro, nsụkọ mkpụrụ ndụ na oke ịmụ nwa, egosighi otu ihe ize ndụ nye mmadụ.

N'ime nyocha nke vitro, gụnyere njikọta insulin na ndị na-anabata IGF-1 yana mmetụta na uto mkpụrụ ndụ, insulin aspart kpara ike dị ka insulin mmadụ. Nnyocha e mere egosiwo na ịhapụ njikọ nke ndị na-anabata insulin maka insulin aspart bụ ya na insulin mmadụ.

Mpempe usoro onunu ogwu

Nkwụsị nke nchịkwa subcutaneous, 100 PIECES / ml

1 ml nke nkwusioru nwere

ike ihe - insulin aspart 100 U (3,5 mg) (30% soulin na insulin aspart na 70% insulin aspart crystallized with protamine),

ndị mgbe ochie: zinc, glycerol, phenol, metacresol, sodium hydrogen phosphate dihydrate, sodium chloride, protamine sulfate, hydrochloric acid, sodium hydroxide, mmiri maka injection.

Echichi na-acha ọcha na-enweghị ntụpọ, n'oge a na-echekwa ya, na-agbanwe agbanwe ka ọ bụrụ nke na-enweghị atụ na nke enweghị agba na nke na-acha ọcha. Mgbe ị na-agwakọta ihe dị na mkpịsị akwụkwọ ahụ, nkwanyekọ ga-etolite.

Usoro onunu ogwu na nhazi

Ezubere NovoMix® 30 FlexPen® naanị maka nchịkwa subcutaneous. Ekwesighi inye NovoMix® 30 FlexPen be intravenia, n'ihi na nke a nwere ike ibute nnukwu hypoglycemia. Ekwesịrị izere nchịkwa intramuscular nke NovoMix® 30 FlexPen®. Ejila NovoMix® 30 FlexPen® maka okpukpo insulin na-akpata insulin (PPII) na nfuli insulin.

Ọ bụ dọkịta ga-ekpebi ọ̀tụ̀tụ̀ ọgwụ ahụ n’otu n’otu n’otu, dabere n’ókè glucose dị n’ọbara.

Ndị ọrịa na-arịa ụdị ọrịa shuga 2, NovoMix® 30 FlexPen® ka enwere ike ịkọwapụta ya dị ka monotherapy yana yana ọgwụ hypoglycemic nke ọnụ na-edeghị usoro nchịkwa hypoglycemic ọnụ naanị.

Maka ndị ọrịa nwere ụdị shuga nke 2, usoro ọgwụgwọ akwadoro nke NovoMix® 30 FlexPen® bụ nkeji 6 n'ụtụtụ yana nkeji 6 na mgbede (nri ụtụtụ na nri abalị, n'otu n'otu). A na-ahapụ ya ka ọ weghara 12 nke NovoMixM 30 FlexPen® otu ugboro n'ụbọchị na mgbede. N'ọnọdụ nke abụọ, ka ịlechara ọgwụ ọgwụ 30, a na-atụ aro ka ọ gbanwee ka ọ na-ewere NovoMix® 30 FlexPen® ugboro abụọ n'ụbọchị, na - ekewa ọnụọgụ ahụ ka ọ bụrụ akụkụ nha (na nri ụtụtụ na nri abalị, na ibe ya). Mgbanwe dị mma na ị Noụ NovoMix® 30 FlexPen® ugboro atọ n'ụbọchị ga-ekwe omume site na ịkekọrịta ụtụtụ ụtụtụ ụzọ abụọ na-ewere akụkụ abụọ ahụ n'ụtụtụ na n'ehihie.

N'ime ndị ọrịa nwere insulin na-eguzogide (dịka ọmụmaatụ, n'ihi oke ibu), enwere ike ịbawanye mkpa nke insulin kwa ụbọchị, na ndị ọrịa nwere resingenous secretion nke insulin, enwere ike belata ya.

A na-atụ aro tebụl na-esote maka ndozi dose:

Ọbara glucose tupu nri

Imegharidoses NovoMix® 30

Ekwesịrị inye NovoMix® 30 FlexPen® ozugbo tupu nri. Ọ bụrụ na ọ dị mkpa, enwere ike ịnye NovoMix® 30 FlexPen® n'oge na-adịghị anya mgbe nri gachara.

Okpomoku nke mmanu insulin kwesiri ino na okpomoku.

Ekwesịrị ịnwe NovoMix® 30 FlexPen sub n'okpuru subcutaneously na apata ụkwụ ma ọ bụ mgbidi akụkụ ihu. Ọ bụrụ na achọrọ, a ga-enye ọgwụ a n'ubu ma ọ bụ buttocks.

Okwesiri igbanwe ebe ogwu ngbanyere na mpaghara anatomical iji gbochie mmepe nke lipodystrophy.

Dị ka ọ dị na nhazi insulin ọ bụla, oge ọrụ NovoMix® 30 FlexPen® na-adabere na ntinye, ebe nchịkwa, ike ọbara na-erugharị, ọnọdụ okpomọkụ na ọkwa nke mmega ahụ. Agụbeghị mmesi maka nnabata nke NovoMix® 30 FlexPen® na saịtị ịgba agba.

Ọ ga-adị mkpa imeghari dose ma ọ bụrụ na onye ọrịa ahụ nwere ọrịa ndị akụrụ, akụrụ, ọrụ akwara, pisis gland ma ọ bụ azụ gland.

Mkpa maka ịhazigharị dose nwekwara ike ibili mgbe ị na-agbanwe mmega ahụ ma ọ bụ nri ndị ọrịa na-emebu. Imezi dose mgbe ị na-ebufe onye ọrịa n’otu ụdị insulin na nke ọzọ.

Ndị okenye na ndị okenye maara ọrụ

Enwere ike iji NovoMix® 30 FlexPen® na ndị ọrịa meworo agadi, agbanyeghị, ahụmịhe ya na ojiji ya na ọgwụ hypoglycemic ọgwụ na ndị ọrịa gbara afọ 75 nwere mmachi.

N'ime ndị ọrịa nwere akụrụ gbasara akwara ma ọ bụ ọrịa hepatic, enwere ike belata mkpa nke insulin.

N'ime ndị ọrịa agadi, ọ dị mkpa iji nyochaa ọkwa glucose ọbara ma mezie ọnụọgụ nke aspart insulin dabere na data ndị mmadụ.

Childrenmụaka na ndị nọ n'afọ iri na ụma

Enwere ike iji NovoMix® 30 FlexPen® gwọọ ụmụaka na ndị nọ n'afọ iri n’agbata afọ 10 n ’ebe a ka ahọrọ ọgwụ insulin gwakọtara. Enwere amachi data gbasara ụlọ ọgwụ maka ụmụaka ruru afọ 6 ruo 9.

Kpachara anya maka eji:

NovoMix® 30 FlexPen® na agịga bụ maka ọdịmma onwe. Ejikwala kadi sirinji.

Enweghị ike iji NovoMix® 30 FlexPen® ma ọ bụrụ na agwakọta ya na-acha ọcha na igwe ojii.

Ọ dị mkpa ịgwakọta nkwusioru NovoMix® 30 FlexPen® ozugbo iji ya. Ejila NovoMix® 30 FlexPen® ma ọ bụrụ na agbajikwala. Tụfuo agịga ahụ mgbe ị gbasasịrị nke ọma.

Nsonaazụ

Mmeghachi omume ọjọọ na-achọpụta na ndị ọrịa na-eji NovoMix® 30 FlexPen® na-abụkarị ọgwụ na-adabere ma na-esite na ọgwụ insulin.

Ihe ndị a bụ ụkpụrụ nke ugboro ole nke mmeghachi omume ojoo achoputara n'oge ọnwụnwa nke ụlọ ọgwụ, nke e lere anya dịka o jikọtara ya na iji NovoMix® 30 FlexPen®. Ekpebisiri ugboro ole a dịka nke a: ọtụtụ mgbe (≥ 1/10), ọtụtụ mgbe (≥ 1/100 ruo

Leasedị mwepụta, nkwakọ ngwaahịa na ihe mejupụtara

Nkwụsị ahụ maka nchịkwa s / c nke agba ọcha, imekọ (na-enweghị nhịahụ, flakes nwere ike ịpụta na nlele ahụ), mgbe ekewapụ, delaminates, na-akpụ ụcha ọcha na nke enweghị agba ma ọ bụ nke na-enweghị ụcha, na-eji nwayọọ na-akpali akpali nke mbido, nkwụchi edo edo kwesịrị ịmalite.

Ndị pụrụ iche: glycerol - 16 mg, phenol - 1.5 mg, metacresol - 1.72 mg, zinc chloride - 19.6 μg, sodium chloride - 0.877 mg, sodium hydrogen phosphate dihydrate - 1.25 mg, protamine sulfate

0.33 mg sodium hydroxide

2.2 mg, hydrochloric acid

1.7 mg, mmiri d / i - ruo 1 ml.

3 ml (300 PIECES) - katrized (5) - blisters (1) - ngwugwu nke kaadiboodu.

Omume ọgwụ

Ọ bụ nkwusioru nke okpukpu abụọ nke mejupụtara ọgwụ insulin analogues: insulin aspart (30% insulin analog) na insulin kristal nke aspart protamine (70% ọkara insulin analog).

Mbelata nke glucose ọbara na-apụta n'ihi mmụba na njem ya n'ime intracellular mgbe mmịnye insulin aspart biphasic ya na ndị na-anabata insulin nke uru ahụ na akwara adi adi yana imeju n’otu oge na - egbochi imepụta glucose site na imeju.

Mmetụta akụkụ

N'akụkụ nke sistem ahụ ji alụso ọrịa ọgụ: ugboro ugboro - urticaria, ọnya anụ ahụ, ihe ọkụ anụ ahụ, ọ na-adịkarị obere - mmeghachi omume anaphylactic.

Site n'akụkụ nke metabolism na nri nri: ọtụtụ mgbe - hypoglycemia.

Site n'akụkụ nke sistem ụjọ: adịkarịghị - neuropathy na-agbatị (nnukwu ụfụ neuropathy).

Site n'akụkụ akụkụ ahụ nke ọhụụ: ugboro ugboro - njehie na -eme ka ụbụrụ, ọrịa retinopathy na-arịa ọrịa shuga.

Site na anụ ahụ na akwara dị n'okpuru ala: obere oge - lipodystrophy.

Mmeghachi omume izugbe: edere ugboro ugboro - edema.

Ime na lactation

Ahụmahụ na-adakarị na ịtụrụ ime nwere oke.

N'oge oge ọ ga-ekwe omume ịtụrụ ime, na oge ya niile, ọ dị mkpa iji nlezianya nyochaa ọnọdụ nke ndị ọrịa nwere ọrịa mellitus ma lelee oke glucose n'ọbara. Mkpa insulin, dị ka a na-achị, na-ebelata na ọkara nke mbụ wee jiri nwayọọ nwayọọ na-abawanye na nke abụọ na nke atọ nke afọ ime. N'oge na-adịghị anya a mụsịrị nwa, mkpa ọ dị insulin na-alaghachi ngwa ngwa dị ka ọ dị tupu ime ime.

N'oge a na-enye nwa ara, enwere ike iji ya na enweghị mgbochi. Ijikwa insulin na-a motherụ ara na-eme nne abụghị ihe egwu nye nwa a. Agbanyeghị, ịgbazigharị ọgwụ nwere ike ịdị mkpa.

Jiri na umuaka

A naghị akwado ya maka ụmụaka na-erubeghị afọ isii, dịka Emebeghị nnwale ụlọ ọgwụ.

Enwere ike iji ya mee ihe iji gwọọ ụmụaka na ndị nọ n’afọ iri n’agbata afọ 10 n’ebe a ka họọrọ ọgwụ insulin gwakọtara. Enwere amachi data gbasara ụlọ ọgwụ maka ụmụaka ruru afọ 6–9.

Ntụziaka pụrụ iche

Tupu ogologo njem metụtara mgbanwe oge mpaghara, onye ọrịa ahụ kwesịrị ịkpọtụrụ dọkịta ha, ebe ịgbanwe oge mpaghara pụtara na onye ọrịa ahụ ga-eri ya ma nyekwa ya insulin n'oge dị iche.

Ọgwụ ezughị oke nke ọgwụ ma ọ bụ ịkwụsị ọgwụgwọ, karịsịa na ụdị ọrịa shuga 1 nke ọrịa mellitus, nwere ike iduga mmepe nke hyperglycemia ma ọ bụ ketoacidosis mamịrị. Dịka iwu, mgbaàmà mbụ nke hyperglycemia pụtara nke nta nke nta, ọtụtụ awa ma ọ bụ ụbọchị. Ihe mgbaàmà nke hyperglycemia bụ mmetụta akpịrị ịkpọ nkụ, mmụba na mmụba a tọhapụrụ, ọgbụgbọ, ọgbụgbọ, ụra, akpịrị na akpịrị, akpịrị ịkpọ nkụ, agụụ, na ọdịdị nke acetone na ikuku nwere oke. Enweghị ọgwụgwọ kwesịrị ekwesị, hyperglycemia na ndị ọrịa nwere ọrịa shuga 1 nwere ike ibute ketoacidosis mamịrị, ọrịa na-egbu egbu.

Izere nri ma ọ bụ imega ahụ siri ike na-enweghị nhazi nwere ike iduga hypoglycemia. Hypoglycemia nwekwara ike ịmalite ma ọ bụrụ na ọgwụ insulin dị oke na mkpa onye ọrịa.

Mgbe ha kwusịrị metabolism metabolism, dịka ọmụmaatụ, na ọgwụ insulin ike, ndị ọrịa nwere ike
akara ngosipụta nke mgbanwe nke hypoglycemia mgbanwe, nke ekwesịrị ịgwa ndị ọrịa banyere. Ihe mgbaàmà ịdọ aka na ntị na-adịkarị nwere ike ịnwe ọrịa shuga ogologo oge.

Ọrịa concoitant, nke na-efe efe ma na-efe efe, na -emekarị ahụ insulin nwere ahụ. Ọ ga-adịkwa mkpa iji dozigharị dose ma ọ bụrụ na onye ọrịa nwere ọrịa nke akụrụ, imeju, ọrụ na-arịa ya, ma ọ bụ gland gland.

Mgbe ị na-ebufe onye ọrịa na ụdị insulin ndị ọzọ, ihe mgbaàmà mbụ nke ebido hypoglycemia nwere ike gbanwee ma ọ bụ belata ịkpọ aha karịa ndị na-eji ụdị insulin mbụ.

A ga-ebufe onye ọrịa na ụdị insulin ọ bụla ma ọ bụ ịkwado insulin nke onye nrụpụta ọzọ n'okpuru nlekọta ahụike siri ike. Ọ bụrụ ngbanwe ịta, ụdị, onye na-emepụta ihe na ụdị (insulin mmadụ, analog nke insulin mmadụ) na nkwadebe insulin na / ma ọ bụ usoro imepụta, enwere ike ịchọrọ ịgbanwe dose.

A kọwo ọrịa banyere mmepe nke obi nkụda mmụọ na ọgwụgwọ nke ndị ọrịa nwere thiazolidinediones yana njikọ insulin, ọkachasị ma ọ bụrụ na ndị ọrịa dị otú ahụ nwere ihe ọghọm maka mmepe nke ọrịa obi na-adịghị ala ala. Ekwesiri iburu n'uche eziokwu a mgbe ị na-edepụta ọgwụ njikọta na thiazolidinediones na nkwadebe insulin na ndị ọrịa. Mgbe ị na-edepụta usoro ọgwụgwọ dị otú a, ọ dị mkpa iji nyochaa nyocha ahụike nke ndị ọrịa iji chọpụta akara na akara nke obi na-adịghị ala ala, oke ibu na ọnụnọ edema. Ọ bụrụ na mgbaàmà nke nkụda obi na-akawanye njọ n'ime ndị ọrịa, a ga-akwụsị ịgwọ ya na thiazolidinediones.

Mmetụta ikike ịkwọ ụgbọala na usoro

Ike nke ndị ọrịa itinye uche na ọnụego mmeghachi omume nwere ike ọfụma n'oge hypoglycemia, nke nwere ike ịdị ize ndụ n'ọnọdụ ebe ikike ndị a dị ezigbo mkpa (dịka ọmụmaatụ, mgbe ha na-anya ụgbọala ma ọ bụ jiri igwe na arụ ọrụ).

A dụrụ ndị ọrịa ọdụ ka ha mee ihe iji gbochie mmepe nke hypoglycemia mgbe ha na-anya ụgbọala. Nke a dị ezigbo mkpa maka ndị ọrịa enweghị ọrịa ma ọ bụ nwee mbelata nke ọrịa ọrịa na-etolite hypoglycemia ma ọ bụ na-ata ahụhụ site na ọrịa hypoglycemia ugboro ugboro. N'ụdị ndị a, ekwesịrị ịtụle maka ịkwọ ụgbọala na ịrụ ụdị ọrụ ahụ.

Mkparịta ụka ọgwụ ọjọọ

E nwere ọtụtụ ọgwụ na-emetụta mkpa maka insulin. Hypoglycemic mmetụta nke insulin welie onu hypoglycemic ọgwụ ọjọọ, Mao inhibitors, Ace inhibitors, carbonic anhydrase inhibitors adịghị nhọrọ beta-blockers, bromocriptine, sulfonamides, anabolic Steroid, tetracyclines, clofibrate, ketoconazole, mebendazole, pyridoxine, theophylline, cyclophosphamide, fenfluramine, ọgwụ ọjọọ lithium salicylates .

Mmetụta hypoglycemic mmetụta nke insulin na-ebelata site na mgbochi ogwu, glucocorticosteroids, homonụ thyroid, thiazide diuretics, heparin, tricyclic antidepressants, sympathomimetics, somatropin, danazole, clonidine, ngwa ngwa calcium channel blockers, diazoxide, morphine.

Ndị na-egbochi mkpọtụ na-ekpuchi ihe mgbaàmà hypoglycemia.

Octreotide / lanreotide nwere ike ịbawanye ma wedata mkpa ahụ insulin nwere.

Mmanya na-egbu egbu nwere ike iwelie ma ọ bụ ibelata mmetụta hypoglycemic nke insulin.